4-aminopyridine for Skin Wound Healing

Part of paid clinical trials in Tucson, Arizona.

Sponsor
John Elfar
Study ID
NCT06333171
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Wound Heal
  • Wound of Skin
  • Wounds
  • Wounds and Injuries

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • 4-Aminopyridine — DRUG
    Active study drug
  • Placebo — OTHER
    Placebo comparator

Study Details

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults. The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing. The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.

Key Dates

Start date
Sep 30, 2025
Status verified
Sep 2025
Primary completion
Sep 30, 2027
Completion
Mar 31, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A: 4-aminopyridine
    dalfampridine (generic) 10 mg capsule po every 12 hours
  • Placebo Comparator: Group B: Placebo
    Placebo-1 capsule po every 12 hours

Primary Outcome Measure

Return of skin integrity and wound closure after skin punch biopsy [ Time Frame: 6 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ArizonaTucsonArizona85724
Andrea Horne
[email protected]
520-626-6456

Find similar trials in Tucson, AZ

By research site
University of Arizona· Tucson, AZ

Related Studies